4 Healthcare Stock Stories Not To Be Overlooked
moreView todays social media effects on PRANView the latest stocks trending across Twitter. Click to view dashboardSee who Prana is hiring next, click here to view […]
PRAN
Prana’s PBT434 Inhibits Accumulation of Parkinson’s Protein and Subsequent Death of Brain Cells.
[Marketwired] – Prana Biotechnology today announced that PBT434, Prana’s lead drug candidate for Parkinson’s Disease and movement disorders, will be presented at two international conferences in March. The key finding … moreView todays social media effects on PRANView the latest stocks trending across Twitter. Click to view dashboardSee who Prana is hiring next, click here to view […]
Prana’s PBT434 Inhibits Accumulation of Parkinson’s Protein and Subsequent Death of Brain Cells
[at noodls] – Prana’s PBT434 Inhibits Accumulation of Parkinson’s protein and Subsequent Death of Brain Cells….This is an abstract of the original noodl. To continue reading this document, click here for the original … moreView todays social media effects on PRANView the latest stocks trending across Twitter. Click to view dashboardSee who Prana is hiring next, click here to view […]
Prana Announces That PBT2 Reduces Cognitive Impairment Caused by Tau Protein Accumulation
moreView todays social media effects on PRANView the latest stocks trending across Twitter. Click to view dashboardSee who Prana is hiring next, click here to view […]
Prana Announces New York Academy of Sciences Symposium eBriefing Available Online
[at noodls] – Prana Announces that New York Academy of Sciences eBriefing available online ‘Targeting Metals in Alzheimer’s and Other Neurodegenerative Diseases’ Symposium Melbourne – January 30, 2013; Prana Biotechnology … moreView todays social media effects on PRANView the latest stocks trending across Twitter. Click to view dashboardSee who Prana is hiring next, click here to view […]
Prana Completes Recruitment in Huntington Trial
[at noodls] – 6 month Phase II study with PBT2 in Huntington patients Melbourne – 19 December, 2012: Prana Biotechnology (NASDAQ:PRAN; ASX:PBT) today announced that it has completed recruitment in the Reach2HD Phase … moreView todays social media effects on PRANView the latest stocks trending across Twitter. Click to view dashboardSee who Prana is hiring next, click here to view […]
Journal of Huntington’s Disease Publishes Benefits of PBT2
[at noodls] – Journal of Huntington’s Disease Publishes Benefits of PBT2 Melbourne – December 13, 2012; Prana Biotechnology (NASDAQ:PRAN; ASX:PBT) today announced that the Journal of Huntington’s Disease has in its … moreView todays social media effects on PRANView the latest stocks trending across Twitter. Click to view dashboardSee who Prana is hiring next, click here to view […]
Prana to Present at New York Academy of Science Symposium
[at noodls] – Prana to present at New York Academy of Science Symposium on November 29th Targeting Metals in Alzheimer’s and Other Neurodegenerative Diseases Melbourne – November 20, 2012; Prana Biotechnology … moreView todays social media effects on PRANView the latest stocks trending across Twitter. Click to view dashboard […]
Prana Provides Huntington Disease Trial Update
[at noodls] – in conjunction with the Huntington Study Group Annual Conference Melbourne – 14 November, 2012; Prana Biotechnology (NASDAQ:PRAN; ASX:PBT) today reported on its progress in the Reach2HD trial, following … moreView todays social media effects on PRANView the latest stocks trending across Twitter. Click to view dashboard […]
Prana Announces A$6 Million Capital Raising
[at noodls] – Prana Announces A$6.0 Million Capital Raising Melbourne – October 1, 2012 : Prana Biotechnology Limited (NASDAQ:PRAN; ASX:PBT) today announced that it has raised A$6.0 million (approx.) through a placement … moreView todays social media effects on PRANView the latest stocks trending across Twitter. Click to view dashboard […]
